Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ: FULC )

4.050 -0.040 (-0.98%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fulcrum Therapeutics, Inc. (FULC) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces CEO Transition
Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.